Cargando…
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study
OBJECTIVE: Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (I...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161302/ https://www.ncbi.nlm.nih.gov/pubmed/21788624 http://dx.doi.org/10.2337/dc11-0545 |
_version_ | 1782210672213360640 |
---|---|
author | Barzilay, Joshua I. Gao, Peggy Rydén, Lars Schumacher, Helmut Probstfield, Jeffrey Commerford, Patrick Dans, Antonio Ferreira, Rafael Keltai, Mátyás Paolasso, Ernesto Yusuf, Salim Teo, Koon |
author_facet | Barzilay, Joshua I. Gao, Peggy Rydén, Lars Schumacher, Helmut Probstfield, Jeffrey Commerford, Patrick Dans, Antonio Ferreira, Rafael Keltai, Mátyás Paolasso, Ernesto Yusuf, Salim Teo, Koon |
author_sort | Barzilay, Joshua I. |
collection | PubMed |
description | OBJECTIVE: Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. RESEARCH DESIGN AND METHODS: Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. RESULTS: During a median 56 months, 21.8% of participants treated with telmisartan and 22.4% of those on placebo developed diabetes (relative ratio 0.95 [95% CI 0.83–1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo. CONCLUSIONS: There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes. |
format | Online Article Text |
id | pubmed-3161302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-31613022012-09-01 Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study Barzilay, Joshua I. Gao, Peggy Rydén, Lars Schumacher, Helmut Probstfield, Jeffrey Commerford, Patrick Dans, Antonio Ferreira, Rafael Keltai, Mátyás Paolasso, Ernesto Yusuf, Salim Teo, Koon Diabetes Care Original Research OBJECTIVE: Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. RESEARCH DESIGN AND METHODS: Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. RESULTS: During a median 56 months, 21.8% of participants treated with telmisartan and 22.4% of those on placebo developed diabetes (relative ratio 0.95 [95% CI 0.83–1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo. CONCLUSIONS: There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes. American Diabetes Association 2011-09 2011-08-19 /pmc/articles/PMC3161302/ /pubmed/21788624 http://dx.doi.org/10.2337/dc11-0545 Text en © 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Original Research Barzilay, Joshua I. Gao, Peggy Rydén, Lars Schumacher, Helmut Probstfield, Jeffrey Commerford, Patrick Dans, Antonio Ferreira, Rafael Keltai, Mátyás Paolasso, Ernesto Yusuf, Salim Teo, Koon Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study |
title | Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study |
title_full | Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study |
title_fullStr | Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study |
title_full_unstemmed | Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study |
title_short | Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study |
title_sort | effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the transcend study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161302/ https://www.ncbi.nlm.nih.gov/pubmed/21788624 http://dx.doi.org/10.2337/dc11-0545 |
work_keys_str_mv | AT barzilayjoshuai effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT gaopeggy effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT rydenlars effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT schumacherhelmut effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT probstfieldjeffrey effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT commerfordpatrick effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT dansantonio effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT ferreirarafael effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT keltaimatyas effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT paolassoernesto effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT yusufsalim effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT teokoon effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy AT effectsoftelmisartanonglucoselevelsinpeopleathighriskforcardiovasculardiseasebutfreefromdiabetesthetranscendstudy |